Blood Test Checks Leukemia Stem Cells to Help Predict Childhood Leukemia Relapse
Studies blood and marrow cells in children with leukemia to predict relapse.
Plain-language title generated from the registry record
Registry title: Using Multiparametric Flow Cytometry to Detect Peripheral Blood and Bone Marrow Leukaemia Stem Cells for Relapse Prediction in P-AML
Key facts
- Where
- Beijing, ChinaSee the 2 sites
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for children and teenagers newly diagnosed with acute myeloid leukemia. Blood tests will look for leukemia stem cells to predict relapse.
- Age
- 18 years or younger
- Sex
- All sexes can join.
- Disease stage
- Newly diagnosed acute myeloid leukemia.
Main reasons for not taking part
- Cannot comply with the study
- Severe heart disease (ejection fraction below 50%)
- Severe liver disease (total bilirubin above 34umol/L, ALT and AST above 1.5 times the upper limit of normal)
- Kidney disease (serum creatinine above 130umol/L (1.47 mg/dL))
- Severe infection
Read by machine on 12 November 2026.
Where in China
- Peking University People's HospitalBeijing, ChinaContact: Yingjun Chang Y Prof. Ying-Jun Chang ChangTaking people
- People's Hospital of Peking UniversityBeijing, ChinaContact: Ying-Jun ChangTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Peking University People's Hospital
- Trial code
- NCT06452732
- Record updated
- 31 December 2025
- Original description
Leukaemia is a major disease that seriously endangers human health, the long-term survival rate of acute myeloid leukaemia receiving conventional chemotherapy is only 10% to 45%, haematological relapse is the main cause of treatment failure in acute myeloid leukaemia, reducing the relapse rate is the key to improving the efficacy of acute leukaemia, biomarker-guided preemptive therapy is an effective way to reduce the recurrence of leukaemia, existing markers to predict the recurrence has a high false Existing markers have high false-negative and false-positive rates for predicting relapse, and improving the accuracy of leukaemia relapse prediction is a major clinical problem that needs to be solved urgently. The group has found that circulating leukaemia stem cells remaining after chemotherapy are the key to relapse, therefore, we propose to conduct a multicentre prospective clinical study on the prediction of acute leukaemia relapse by circulating leukaemia stem cells.Read full original descriptionShow less
Using Multiparametric Flow Cytometry to Detect Peripheral Blood and Bone Marrow Leukaemia Stem Cells for Relapse Prediction in Pediatric Acute Myeloid Leukaemia: a Prospective Study
Leukaemia is a major disease that seriously endangers human health, the long-term survival rate of acute myeloid leukaemia receiving conventional chemotherapy is only 10% to 45%, haematological relapse is the main cause of treatment failure in acute myeloid leukaemia, reducing the relapse rate is the key to improving the efficacy of acute leukaemia, biomarker-guided preemptive therapy is an effective way to reduce the recurrence of leukaemia, existing markers to predict the recurrence has a high false Existing markers have high false-negative and false-positive rates for predicting relapse, and improving the accuracy of leukaemia relapse prediction is a major clinical problem that needs to be solved urgently. The group has found that circulating leukaemia stem cells remaining after chemotherapy are the key to relapse, therefore, we propose to conduct a multicentre prospective clinical study on the prediction of acute leukaemia relapse by circulating leukaemia stem cells.
Inclusion: Newly diagnoses candidates with acute myeloid leukemia; Lower than or equal to 18 years-old; Subjects are able to provide written informed consent.
Exclusion: Subjects with severe infection; Subjects with other conditions that cannot receive chemotherapy or transplantation; Subjects with severe cardiac disease (ejection fraction<50% ), liver disease (total bilirubin >34umol/L, ALT and AST>1.5×upper limit normal) or kidney disease (Serum creatinine>130umol/L); Subjects who cannot comply with the study.